Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia

University of Arkansas at Little Rock, Little Rock, Arkansas, United States
Cancer (Impact Factor: 4.9). 07/2005; 104(1):199-204. DOI: 10.1002/cncr.21142
Source: PubMed

ABSTRACT Invasive fungal infections (IFI) in immunocompromised patients are associated with significant morbidity and mortality, despite appropriate antifungal treatment and recovery from neutropenia. The outcome of these infections depends significantly on the overall state of immunosuppression, including mainly the phagocytic system (neutrophils and macrophages). Interferon-gamma (IFN-gamma), granulocyte-colony--stimulating factor (G-CSF) and granulocyte-macrophage-colony--stimulating factor (GM-CSF) are cytokines that enhance the activity of neutrophils and macrophages.
The authors reported 4 patients with leukemia and refractory invasive candidiasis or trichosporonosis despite 1-13 months of appropriate antifungal treatment.
Cytokines were administered for 1.5-5 months without significant toxicity. For each patient, initiation of interferon-gamma plus a colony-stimulating factor resulted in a clinical response. The contribution of cytokines to control the fungal infection in these 4 patients was suggested by the strong inflammatory reaction observed in the 2 patients who had an immediate response (within 7 days of initiation of cytokine therapy) and by the good outcome in the 2 other patients in whom antifungal agents were discontinued at the start of cytokine therapy.
These data suggested a potential role for immunomodulation in patients with leukemia with refractory invasive fungal infections.

Download full-text


Available from: Ka Wah Chan, Oct 19, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with hematologic malignancies and hematopoietic stem cell transplant recipients have a broad range of immune deficits that predispose to common and opportunistic infectious diseases. Infectious complications are a major cause of morbidity and mortality in these patients. Effective immune augmentation strategies used as prophylaxis and as adjunctive therapy represent an important unmet need. We discuss several immune-based strategies tailored to specific patient populations. These include strategies to augment neutrophil number, enhance function of neutrophils and macrophages, passive antibody therapy, and augmentation of cellular immunity. We evaluate immune-based therapies that are currently available and the evidence supporting their use. There is a large “pipeline” of novel and promising immunotherapies that are at preclinical and early stages of clinical development. These include augmentation of innate and antigen-specific immunity by stimulating pathogen recognition pathways, adoptive transfer of cellular immunity, and vaccine development. We review these more cutting-edge approaches, with an emphasis on opportunistic fungal and viral infections. We discuss gaps in knowledge and challenges in bringing promising immune-based therapies to clinical trials.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Supportive care issues play a very prominent role in the management of malignant disease. In this context, “supportive care” includes the prevention and treatment of both the complications of anti-neoplastic therapy and of the cancer itself. It is recognized that many of the increasingly effective intensive management strategies now used in oncologic practice could not be employed in the absence of a thorough understanding of these processes, and the development of helpful therapeutic approaches. In this chapter a number of supportive care topics, recently highlighted in the published peer-reviewed literature, are discussed. These include: (a) factors which predict for the development of various types of infectious events (bacterial, viral, fungal) in specific malignancies; (b) the clinical utility of oral versus intravenous antibiotics; (c) the benefits of prophylactic antibiotic therapy (d) outpatient management of neutropenic fever; (e) strategies to optimally manage bacterial, viral and fungal infections in cancer patients; (f) complications associated with the use of indwelling intravenous catheter systems in the oncology patient population and methods to both manage and prevent such events; (g) new developments in anti-emetic therapy; and (h) and a novel strategy to prevent treatment-associated mucositis.
    Cancer chemotherapy and biological response modifiers 02/2005; 22(2):677-86. DOI:10.1016/j.uct.2006.04.009
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The spectrum of infectious diseases has shifted in the past 50 years to include those caused by microbes that cause disease predominantly in immunocompromised individuals. This phenomenon has underscored the dependence of microbial virulence on the immune status of the host. The limited efficacy of the available antimicrobial armamentarium in immunocompromised individuals, combined with increasing resistance to these agents, has led to an urgent need for new therapies for infectious diseases. Immunomodulation represents a novel approach to antimicrobial therapy that depends on bolstering host immunity, rather than direct antimicrobial activity. Immunomodulators can be divided into those that are specific to pathogens (pathogen-specific) and those that are not specific to pathogens (non-specific). However, to date only a few immunomodulators have been evaluated for their efficacy as antimicrobial tools.
    Current Opinion in Microbiology 11/2006; 9(5):489-95. DOI:10.1016/j.mib.2006.08.004 · 7.22 Impact Factor
Show more